Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Severe haematological complications during treatment with natalizumab.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
Disease-modifying drugs for multiple sclerosis and JC virus expression.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Substance Name: Naltrexone
Drugs to be Discontinued
Multiple sclerosis treatment: current best practice.
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Disease-modifying therapies in Chinese children with multiple sclerosis.
CD46: The 'multitasker' of complement proteins.
Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study.
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
Vitamin D: a natural inhibitor of multiple sclerosis.
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q).
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
Monosymptomatic clinically isolated syndrome with sudden sensorineural hearing loss: case report and critical review of the literature.
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.

Pages